NASDAQ:HALO

Halozyme Therapeutics Stock Forecast, Price & News

$41.14
-1.03 (-2.44 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$40.75
$42.13
50-Day Range
$38.84
$46.42
52-Week Range
$25.17
$56.40
Volume768,321 shs
Average Volume1.15 million shs
Market Capitalization$5.86 billion
P/E Ratio36.41
Dividend YieldN/A
Beta1.47
30 days | 90 days | 365 days | Advanced Chart
Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Halozyme Therapeutics logo

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; and Centre for the AIDS Programme of Research in South Africa. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

97th out of 2,218 stocks

Biological Products, Except Diagnostic Industry

13th out of 213 stocks

Analyst Opinion: 3.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Halozyme Therapeutics?

Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Halozyme Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its earnings results on Monday, May, 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.32 by $0.05. The biopharmaceutical company had revenue of $89.02 million for the quarter, compared to the consensus estimate of $84.88 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 174.48% and a net margin of 49.23%. The company's revenue for the quarter was up 251.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.04) EPS.
View Halozyme Therapeutics' earnings history
.

How has Halozyme Therapeutics' stock been impacted by COVID-19?

Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HALO shares have increased by 125.8% and is now trading at $41.14.
View which stocks have been most impacted by COVID-19
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $1.550-1.700 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.550. The company issued revenue guidance of $375 million-395 million, compared to the consensus revenue estimate of $389.96 million.

What price target have analysts set for HALO?

8 brokerages have issued 1-year price objectives for Halozyme Therapeutics' stock. Their forecasts range from $41.00 to $65.00. On average, they expect Halozyme Therapeutics' stock price to reach $54.14 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 58, Pay $1.52M)
  • Ms. Elaine D. Sun, Sr. VP & CFO (Age 49, Pay $859.58k)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 57, Pay $710.18k)
  • Mr. Masaru Matsuda Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $707.84k)
  • Mr. Ed Gemo, VP, Chief Information & Security Officer
  • Mr. Albert S. Kildani, VP of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox, VP of HR
  • Mr. William J. Fallon, Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances (Age 64)
  • Dr. Steve Knowles, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Tran Capital Management L.P. (0.95%), Scout Investments Inc. (0.22%), Brookstone Capital Management (0.04%), Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics
.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Tran Capital Management L.P.. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics
or view top insider-selling stocks.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including Brookstone Capital Management, New Mexico Educational Retirement Board, Oregon Public Employees Retirement Fund, EFG Asset Management Americas Corp., and State of Alaska Department of Revenue.
View insider buying and selling activity for Halozyme Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $41.14.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of $5.86 billion and generates $267.59 million in revenue each year. The biopharmaceutical company earns $129.09 million in net income (profit) each year or $0.91 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 147,000 workers across the globe.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

Where are Halozyme Therapeutics' headquarters?

Halozyme Therapeutics is headquartered at 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.